IGA Glomerulonephritis
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
IgA nephropathy-specific expression of the IgA Fc receptors (CD89) on blood phagocytic cells.
|
9367406 |
1997 |
Primary immunoglobulin A nephropathy (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, the binding of aIgA2 to CD89 was less inhibited using mIgA from patients with IgAN compared to controls.
|
9870466 |
1998 |
IGA Glomerulonephritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice.
|
10839814 |
2000 |
IGA Glomerulonephritis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms in the promoter and 5' UTR region of the Fc alpha receptor (CD89) are not associated with a risk of IgA nephropathy.
|
11776381 |
2001 |
Renal glomerular disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We screened genomic DNA samples from patients with IgAN and those with other glomerular diseases for polymorphisms in the promoter and the 5'-untranslated region region of the FcalphaR gene by direct nucleotide sequencing.
|
11776381 |
2001 |
Gram-negative bacteremia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Enhanced expression of Fc alpha receptor I on blood phagocytes of patients with gram-negative bacteremia is associated with tyrosine phosphorylation of the FcR-gamma subunit.
|
11699071 |
2001 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Previous studies have demonstrated that, in addition to IgG Fc receptors, the human myeloid IgA receptor (Fc(alpha)RI, CD89) also effectively triggered tumor cell killing.
|
12393717 |
2002 |
beta Thalassemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Otherwise, Hb Korea, CDs 89/90 -GT and a novel beta-thalassemia mutation, CD 131 CAG-->TAG, were only identified in Koreans.
|
12430907 |
2002 |
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Binding, internalization, and catabolic degradation of myeloma IgA1 protein as a standard control and the isolated CIC were studied using human MC, hepatoma cell line HepG2 expressing the asialoglycoprotein receptor (ASGP-R), and monocyte-like cell line U937 expressing the Fc(alpha)-R (CD89).
|
12110007 |
2002 |
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Binding, internalization, and catabolic degradation of myeloma IgA1 protein as a standard control and the isolated CIC were studied using human MC, hepatoma cell line HepG2 expressing the asialoglycoprotein receptor (ASGP-R), and monocyte-like cell line U937 expressing the Fc(alpha)-R (CD89).
|
12110007 |
2002 |
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Binding, internalization, and catabolic degradation of myeloma IgA1 protein as a standard control and the isolated CIC were studied using human MC, hepatoma cell line HepG2 expressing the asialoglycoprotein receptor (ASGP-R), and monocyte-like cell line U937 expressing the Fc(alpha)-R (CD89).
|
12110007 |
2002 |
beta^+^ Thalassemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Otherwise, Hb Korea, CDs 89/90 -GT and a novel beta-thalassemia mutation, CD 131 CAG-->TAG, were only identified in Koreans.
|
12430907 |
2002 |
Acute periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A novel polymorphism of FcalphaRI (CD89) associated with aggressive periodontitis.
|
15140034 |
2004 |
Aggressive Periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A novel polymorphism of FcalphaRI (CD89) associated with aggressive periodontitis.
|
15140034 |
2004 |
Allergic asthma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, this is the first report on the distribution of 6 single nucleotide polymorphisms of the FCAR gene in a human population and the first study on FCAR polymorphism in allergic asthma.
|
15564774 |
2004 |
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
|
17008591 |
2006 |
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that the FCAR promoter SNPs may be related to chronic HCV infection and disease progression in Japanese CHC, which might be explained by altered FcalphaR expression affecting IgA-mediated immune responses and/or IgA catabolism.
|
17033823 |
2006 |
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin.
|
17008591 |
2006 |
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin.
|
17008591 |
2006 |
Hepatitis C, Chronic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.
|
17033823 |
2006 |
Hepatitis C, Chronic
|
0.010 |
Biomarker
|
disease |
LHGDN |
Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.
|
17033823 |
2006 |
Pseudohyperkalemia Cardiff
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that the FCAR promoter SNPs may be related to chronic HCV infection and disease progression in Japanese CHC, which might be explained by altered FcalphaR expression affecting IgA-mediated immune responses and/or IgA catabolism.
|
17033823 |
2006 |
Infection
|
0.010 |
Biomarker
|
group |
LHGDN |
Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.
|
17033823 |
2006 |
Glomerulonephritis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Fc alpha receptor I activation induces leukocyte recruitment and promotes aggravation of glomerulonephritis through the FcR gamma adaptor.
|
17393381 |
2007 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Anti-FcalphaRI Fab treatment of nude mice injected subcutaneously with FcalphaRI+ mast-cell transfectants prevented tumor development and halted the growth of established tumors.
|
16990604 |
2007 |